World's Best Scientists 2026 revealed!
Kah Whye Peng

Kah Whye Peng

D-Index & Metrics

Microbiology

D-Index
66
Citations
11611
World Ranking
2454
National Ranking
993

Overview

Kah Whye Peng is affiliated with the Mayo Clinic in the United States and has contributed extensively to research in the fields of medicine and biochemistry, genetics, and molecular biology. Their work spans various subfields, including genetics, epidemiology, surgery, oncology, and infectious diseases.

The scientist's research predominantly focuses on virus-based gene therapy, particularly with applications in oncology and infectious disease treatments. Their contributions also include significant work on CAR-T cell therapy, bladder and urothelial cancer treatments, urological disorders, and viral infectious diseases including cytomegalovirus and herpesvirus infections.

Peng has published in multiple venues, with frequent appearances in the Journal of Clinical Oncology, Molecular Cancer Therapeutics, Molecular Therapy, Cancer Research, and Blood Advances.

Notable recent papers authored or coauthored by Kah Whye Peng include:

  • "Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma" (2022, Blood Advances)
  • "IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers" (2021, mSphere)
  • "Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients" (2020, Molecular Cancer Therapeutics)
  • "Preclinical Safety Assessment of MV-s-NAP, a Novel Oncolytic Measles Virus Strain Armed with an H. pylori Immunostimulatory Bacterial Transgene" (2022, Molecular Therapy - Methods & Clinical Development)
  • "Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers" (2020, Molecular Therapy - Oncolytics)

Kah Whye Peng collaborates regularly with several researchers, with frequent coauthors including:

  • Stephen J. Russell
  • Alice Bexon
  • Nandakumar Packiriswamy
  • Shruthi Naik
  • Lianwen Zhang

The combination of Peng's publication history and coauthorships suggests a multidisciplinary approach integrating clinical oncology, molecular virology, and immunology. Their work on oncolytic viruses and gene therapy further integrates advanced molecular therapies with clinical applications.

Best Publications

  • High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus.

    Bambi D. Anderson;Takafumi Nakamura;Stephen J. Russell;Kah Whye Peng

  • Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter

    David Dingli;Kah Whye Peng;Mary E. Harvey;Philip R. Greipp

  • Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer

    Evanthia Galanis;Lynn C. Hartmann;William A. Cliby;Harry J. Long

  • Rescue and propagation of fully retargeted oncolytic measles viruses.

    Takafumi Nakamura;Kah Whye Peng;Mary Harvey;Suzanne Greiner

  • Use of a Vaccine Strain of Measles Virus Genetically Engineered to Produce Carcinoembryonic Antigen as a Novel Therapeutic Agent against Glioblastoma Multiforme

    Loi K. Phuong;Cory Allen;Kah Whye Peng;Caterina Giannini

  • Intraperitoneal Therapy of Ovarian Cancer Using an Engineered Measles Virus

    Kah Whye Peng;Cynthia J. TenEyck;Evanthia Galanis;Kimberly R. Kalli

  • Viruses as anticancer drugs

    Stephen J. Russell;Kah Whye Peng

  • Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model

    Emily K. Mader;Yoshihiro Maeyama;Yi Lin;Greg W. Butler

  • Measles virus for cancer therapy.

    Stephen J. Russell;Kah Whye Peng

  • Systemic therapy of myeloma xenografts by an attenuated measles virus

    Kah Whye Peng;Gregory J. Ahmann;Linh Pham;Philip R. Greipp

  • Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides.

    Kah Whye Peng;Suzanne Facteau;Troy Wegman;Dennis O'Kane

  • Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.

    Kah Whye Peng;Kah Whye Peng;Kathleen A. Donovan;Kathleen A. Donovan;Urs Schneider;Urs Schneider;Roberto Cattaneo;Roberto Cattaneo

  • Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer

    Evanthia Galanis;Pamela J. Atherton;Matthew J. Maurer;Keith L Knutson

  • Designing and building oncolytic viruses.

    Justin Maroun;Miguel Muñoz-Alía;Arun Ammayappan;Autumn Schulze

  • Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without Cyclophosphamide

    Myers Rm;Greiner Sm;Harvey Me;Griesmann G

  • Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.

    Ong Ht;Hasegawa K;Dietz Ab;Russell Sj

  • Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma.

    Angela Dispenzieri;Caili Tong;Betsy LaPlant;Martha Q. Lacy

  • Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia

    Weiwei Shen;Mrinal M. Patnaik;Autumn Ruiz;Stephen J. Russell

  • Oncolytic measles virus targets high CD46 expression on multiple myeloma cells

    Hooi Tin Ong;Michael M. Timm;Philip R. Greipp;Thomas E. Witzig

  • Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer

    Emily K. Mader;Greg Butler;Sean C. Dowdy;Andrea Mariani

  • A gene delivery system activatable by disease-associated matrix metalloproteinases.

    Kah Whye Peng;Frances J. Morling;François Loic Cosset;Gillian Murphy

  • Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma

    Boris Blechacz;Patrick L. Splinter;Suzanne Greiner;Rae Myers

Frequent Co-Authors

Evanthia Galanis
Evanthia Galanis Mayo Clinic
Roberto Cattaneo
Roberto Cattaneo Mayo Clinic
François-Loïc Cosset
François-Loïc Cosset Claude Bernard University Lyon 1
Glen N. Barber
Glen N. Barber University of Miami
David Dingli
David Dingli Mayo Clinic
Yasuhiro Ikeda
Yasuhiro Ikeda AstraZeneca (United Kingdom)
Martha Q. Lacy
Martha Q. Lacy Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in microbiology, exploring related fields can broaden career opportunities. Programs such as online health information management degree programs cahiim accredited provide valuable knowledge in managing health data effectively, a skill increasingly important in healthcare settings.

Those seeking a faster entry into the healthcare workforce might consider an accelerated medical billing and coding certificate online. This pathway offers a streamlined approach to gaining certification and can complement microbiology expertise for roles involving medical data and coding.

Exploring online healthcare degrees that pay well can help students align their interests with financially rewarding careers. Many online programs offer flexibility and access to in-demand professions, making it easier to integrate studies with existing commitments.

Additionally, an MPH (Master of Public Health) can enhance career options, especially in research and public health fields. For those concerned about admission selectivity, reviewing easy admission online mph programs can provide practical entry points into advanced public health education.

Best Scientists Citing Kah Whye Peng

Trending Scientists

Recently Published Articles